JP2001512309A - プロテインチロシンキナーゼ２の阻害物質の同定 - Google Patents

プロテインチロシンキナーゼ２の阻害物質の同定

Info

Publication number
JP2001512309A
JP2001512309A JP53507198A JP53507198A JP2001512309A JP 2001512309 A JP2001512309 A JP 2001512309A JP 53507198 A JP53507198 A JP 53507198A JP 53507198 A JP53507198 A JP 53507198A JP 2001512309 A JP2001512309 A JP 2001512309A
Authority
JP
Japan
Prior art keywords
pyk2
compound
ability
cells
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP53507198A
Other languages
English (en)
Japanese (ja)
Inventor
デユオン，ル・テイー
ロダン，ギデオン・エイ
Original Assignee
メルク エンド カンパニー インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルク エンド カンパニー インコーポレーテッド filed Critical メルク エンド カンパニー インコーポレーテッド
Publication of JP2001512309A publication Critical patent/JP2001512309A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
JP53507198A 1997-02-11 1998-02-09 プロテインチロシンキナーゼ２の阻害物質の同定 Pending JP2001512309A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3756097P 1997-02-11 1997-02-11
US60/037,560 1997-02-11
PCT/US1998/002797 WO1998035056A1 (fr) 1997-02-11 1998-02-09 Identification d'inhibiteurs de la proteine tyrosine-kinase 2

Publications (1)

Publication Number Publication Date
JP2001512309A true JP2001512309A (ja) 2001-08-21

Family

ID=21895000

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53507198A Pending JP2001512309A (ja) 1997-02-11 1998-02-09 プロテインチロシンキナーゼ２の阻害物質の同定

Country Status (5)

Country Link
EP (1) EP0968304A1 (fr)
JP (1) JP2001512309A (fr)
AU (1) AU6163398A (fr)
CA (1) CA2277544A1 (fr)
WO (1) WO1998035056A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524374A (ja) * 2003-02-28 2007-08-30 プレキシコン，インコーポレーテッド Ｐｙｋ２結晶構造および使用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6165598A (en) * 1997-02-18 1998-09-08 Lxr Biotechnology Inc. Bak promotor expression system
EP1630559A3 (fr) * 1998-12-30 2006-06-07 Sugen, Inc. PYK2 (RAFTK) et inflammation
WO2000040971A1 (fr) * 1998-12-31 2000-07-13 Sugen, Inc. Pyk2 (raftk) et inflammation
US6861442B1 (en) 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
WO2001083827A1 (fr) * 2000-05-04 2001-11-08 Yale University Reseaux de proteines a haute densite destines au criblage de l'activite de proteines
AU2002236692A1 (en) * 2000-10-23 2002-05-21 Bristol-Myers Squibb Company Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase, their identification and use
EP1401411A2 (fr) * 2001-06-29 2004-03-31 AB Science Utilisation d'inhibiteurs de la tyrosine kinase dans le traitement de la perte osseuse
ATE376182T1 (de) 2001-06-29 2007-11-15 Ab Science C-kit inhibitoren
US7678805B2 (en) 2001-06-29 2010-03-16 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
US7700610B2 (en) 2001-06-29 2010-04-20 Ab Science Use of tyrosine kinase inhibitors for treating allergic diseases
JP2004537537A (ja) 2001-06-29 2004-12-16 アブ サイエンス 炎症性疾患を治療するためのチロシンキナーゼ阻害剤の使用法
MXPA06015170A (es) * 2004-06-21 2007-08-21 Pharmacia & Upjohn Co Llc Procedimiento para aumentar la cantidad de hueso.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524374A (ja) * 2003-02-28 2007-08-30 プレキシコン，インコーポレーテッド Ｐｙｋ２結晶構造および使用

Also Published As

Publication number Publication date
AU6163398A (en) 1998-08-26
CA2277544A1 (fr) 1998-08-13
EP0968304A1 (fr) 2000-01-05
WO1998035056A1 (fr) 1998-08-13

Similar Documents

Publication Publication Date Title
AU697142B2 (en) Protein tyrosine kinases named Rse
Rosen et al. Roles for the integrin VLA-4 and its counter receptor VCAM-1 in myogenesis
JP5089397B2 (ja) 変異ネトリン４、その断片及びこれらの薬剤としての使用
JP2001512309A (ja) プロテインチロシンキナーゼ２の阻害物質の同定
US20140057940A1 (en) Methods for Treating or Preventing Cardiac and Neurological Disorders Using Chemokine Receptor Antagonists
US20070048325A1 (en) Combination therapies for inhibiting integrin-extracellular matrix interactions
JP2002532113A (ja) 切断ｖｅｇｆ−ｄの抗体及びその利用法
JP2011084566A (ja) 新脈管形成抑制のための方法および組成物
Geiger et al. Cytoplasmic control of cell adhesion
JP2007523092A (ja) 新脈管形成阻害のための方法および組成物
US20050221434A1 (en) Receptor of the EDb-fibronectin domains
JP2003259887A (ja) カドヘリン物質および方法
JP2002530066A (ja) Ｒｈａｍｍアンタゴニスト抗体
JP2002501086A (ja) 抗−αｖインテグリンモノクローナル抗体および、フィブロネクチンへのαｖβ６インテグリンの付着を阻害するためのその使用
WO1998025946A1 (fr) Anticorps monoclonaux specifiques des cadherines de cellules endotheliales et leurs utilisations
RU2770006C2 (ru) Антитела к фактору ix padua
CA2660330A1 (fr) Nouvel anticorps monoclonal et son utilisation
WO2000049046A1 (fr) Nouvelle proteine de recepteur couplee a la proteine g et adn
EP2843048B1 (fr) NOUVEAU LIGAND DE L'INTÉGRINE alpha9beta1 ET SES UTILISATIONS
CN111205370B (zh) 抗ptn抗体在抑制白血病干细胞以及治疗慢性粒细胞白血病中的应用
US20090239884A1 (en) Methods of Treating Inflammation
WO2010095270A1 (fr) Anticorps dirigé contre l'intégrine α9 humaine et son utilisation
US20060240002A1 (en) Methods of inhibiting angiogenesis-dependent conditions mediated by cryptic epitopes of extracellular matrix components
US6001621A (en) Protein tyrosine kinases
ZA200302629B (en) Receptor in the EDb fibronectin domain.